Our top pick for
Lumos Pharma Inc is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Lumos Pharma employs 27 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$9.04|
|52-week range||$7.23 - $36.72|
|50-day moving average||$9.91|
|200-day moving average||$10.11|
|Wall St. target price||$27.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.16|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-2.27%|
|1 month (2021-09-24)||-11.02%|
|3 months (2021-07-23)||17.56%|
|6 months (2021-04-23)||-32.74%|
|1 year (2020-10-23)||-37.22%|
|2 years (2019-10-24)||465.00%|
|3 years (2018-10-24)||356.57%|
|5 years (2016-10-24)||14.15|
|Gross profit TTM||$168,000|
|Return on assets TTM||-13.44%|
|Return on equity TTM||-16.5%|
|Market capitalisation||$75.6 million|
TTM: trailing 12 months
There are currently 85,895 Lumos Pharma shares held short by investors – that's known as Lumos Pharma's "short interest". This figure is 12% down from 97,557 last month.
There are a few different ways that this level of interest in shorting Lumos Pharma shares can be evaluated.
Lumos Pharma's "short interest ratio" (SIR) is the quantity of Lumos Pharma shares currently shorted divided by the average quantity of Lumos Pharma shares traded daily (recently around 26267.584097859). Lumos Pharma's SIR currently stands at 3.27. In other words for every 100,000 Lumos Pharma shares traded daily on the market, roughly 3270 shares are currently held short.
However Lumos Pharma's short interest can also be evaluated against the total number of Lumos Pharma shares, or, against the total number of tradable Lumos Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lumos Pharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Lumos Pharma shares in existence, roughly 10 shares are currently held short) or 0.0136% of the tradable shares (for every 100,000 tradable Lumos Pharma shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lumos Pharma.
Find out more about how you can short Lumos Pharma stock.
We're not expecting Lumos Pharma to pay a dividend over the next 12 months.
Lumos Pharma's shares were split on a 1:9 basis on 18 March 2020. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.
Lumos Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.